Comparison of microclimate measurements and perceptions as part of a global evaluation of environmental quality at neighbourhood scale.

The EUREQUA project raises the issue of the definition and evaluation of the environmental quality of neighbourhoods. The approach consists of integrating and cross-referencing observable data characterising the physical environment and people's perception of their quality of life. The study area is a neighbourhood in Toulouse (France) with high social and typo-morphological diversity, subject to noise and air pollution nuisances. Three 3-day field campaigns were organised in January, April, and June 2014. Instrumented and commented walks took place three times per day. For each one, measurements of physical environmental parameters and surveys were performed simultaneously at six locations in the neighbourhood. The study focuses on microclimate and thermal comfort issues. It aims to compare in situ meteorological data of air temperature, humidity, wind speed, and mean radiant temperature, with quantitative results rating human perception of heat, humidity, wind, and thermal comfort. The variability in perception and measurements is mainly driven by seasonal effects, especially for heat and humidity, and, to a lesser extent, for wind. Wind perception and measurement also vary spatially, thus highlighting site effects. Linear models indicate a positive link between heat perception and mean radiant temperature, as well as between wind perception and mean and standard deviation of wind speed (with a higher sensitivity of people to wind under winter climate conditions). Finally, it is found that perception of thermal comfort is only slightly linked to the different microclimate dimensions, and is rather driven by other appreciation factors and emotional criteria related to the general environmental quality of the study area.

Barking up the Right Tree: Using Tree Bark to Track Airborne Particles in School Environment and Link Science to Society.

Children's exposure to air pollution affects both their health and learning skills. Fine and ultrafine particulate matter (PM2.5, PM1), notably issued from traffic sources in urban centers, belong to the most potential harmful health hazards. However their monitoring and the society's awareness on their dangers need to be consolidated. In this study, raising teacher and pupil involvement for air quality improvement in their schools environment is reached through developing a passive monitoring technique (bio-sensors made of tree bark). The experiment was implemented in two urban elementary schools situated close to a main traffic road of the city of Toulouse (South of France). Magnetic properties, carbonaceous fraction measurements, and scanning electronic microscopy (SEM-EDX) investigations were realized both on passive bio-sensors and filters issued from active sampling. We find that traffic is the main PM1 source for both outdoors and indoors at schools. Higher levels of outdoor PM in the school's environments compared to urban background are reached especially in the cold period. The schools proximity to a main traffic source and lack of ventilation are the main causes for observed PM1 accumulation in classrooms. The co-working experiment with educational teams and pupils shows that the use of bio-sensors is a driver for children empowerment to air pollution and therefore represents a potential key tool for the teachers though limiting eco-anxiety. As PM accumulation is observed in many scholar environments across Europe, the proposed methodology is a step toward a better assessment of PM impact on pupil's health and learning skills.

Hospital-based surveillance of invasive pneumococcal disease and pneumonia in South Bangalore, India.

OBJECTIVE: To estimate the incidence of invasive pneumococcal disease and pneumonia, distribution of pneumococcal serotypes, and antibiotic susceptibility in children aged 28 days to <60 months. DESIGN: Hospital-based surveillance. SETTING: South Bangalore, India. PARTICIPANTS: 9950 children aged 28 days to <60 months with clinical suspicion of invasive pneumococcal disease or pneumonia. RESULTS: The estimated at-risk population included 224,966 children <5 years of age. Forty cases of invasive pneumococcal disease were identified. Estimated invasive pneumococcal disease incidence was 17.8/100,000 with incidence being highest among children aged 6 months to <12 months (49.9/100,000). Clinical pneumonia syndrome was the most frequent diagnosis (12.5/100,000). Pneumococcal serotypes included: 6A (n=6, 16.7%); 14 (n=5, 13.9%); 5 (n=4, 11.1%); 6B (n=4, 11.1%); 1, 18C, and 19A (n=3 each, 8.3%); 9V (n=2, 5.6%); and 3, 4, 10C, 18A, 18F, and 19F (n=1 each, 2.8%). Serotypes 6A, 14, 6B, 1, 18C, 19A, 9V, 4, 10C, and 18A showed antibiotic resistance. Clinical pneumonia incidence was 2109/100,000, with incidence being highest among children aged 28 days to <6 months (5033/100,000). Chest radiograph-confirmed pneumonia incidence was 1114/100,000, with incidence being highest among children aged 28 days to <6 months (2413/100,000). CONCLUSIONS: Invasive pneumococcal disease and pneumonia were found to be common causes of morbidity in young children living in South Bangalore, India.

Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.

In a randomized, double-blind, multicenter, multinational, controlled trial, 546 patients with complicated skin and skin structure infections received tigecycline 100 mg/day (a 100-mg initial dose and then 50 mg intravenously twice daily) or the combination of vancomycin 2 g/day (1 g intravenously twice daily) and aztreonam 4 g/day (2 g intravenously twice daily) for up to 14 days. Three hundred eighty-five (385) were from Europe. The primary endpoint was the clinical response in the clinical modified intent-to-treat (c-mITT) and clinically evaluable populations at the test-of-cure visit 12 to 92 days after the last dose. The microbiologic response at the test-of-cure visit was also assessed. Safety was assessed by physical examination, laboratory results and adverse event reporting. Of the patients enrolled in Europe, 376 patients were included in the c-mITT population (tigecycline group, n = 189; vancomycin/aztreonam group, n = 187), and 326 were clinically evaluable (tigecycline group, n = 167; vancomycin/aztreonam group, n = 159). The clinical responses in the tigecycline and the vancomycin/aztreonam groups in the clinically evaluable population were 89.8% versus 95.0%. Microbiologic eradication (documented or presumed) occurred in 84.8% of the European patients receiving tigecycline and 93.2% of the European patients receiving vancomycin/aztreonam. The number of European patients reporting adverse events was similar in the two groups, with increased nausea and vomiting rates in the tigecycline group and an increased incidence of rash and increases in alanine aminotransferase and aspartate aminotransferase levels in the vancomycin/aztreonam group. Current data support findings from the overall results in the Phase 3 study and suggest that tigecycline is safe and effective for the treatment of complicated skin and skin structure infections.

Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.

Soluble Leishmania antigen (SLA) from both developmental stages of L. major (L. major MRHO/IR/75/ER) were prepared. Three and five subfractions of SLA from amastigote and promastigote were obtained by fast protein liquid chromatography (FPLC), respectively. Biochemical analyses and comparison of amastigote and promastigote SLA were done. The biochemical analyses revealed that the first fraction of L. major amastigote possesses a distinct band on its electrophoretic mobility pattern corresponding to a position of 24 kD, and it has enzymatic activity with characteristics of a cysteine proteinase. The isolated fractions of amastigote were tested for induction of proliferation, interferon-gamma (IFN-gamma) and IL-4 production in cultures of peripheral blood mononuclear cells (PBMC) from individuals who had recovered and also chronic patients of cutaneous leishmaniasis caused by L. major. The cells of recovered individuals compared with chronic cases proliferated profoundly in response to the first fraction of amastigote SLA. In all recovered individuals, the IFN-gamma, but not IL-4, was secreted in response to stimulation with the first fraction of amastigote SLA. In chronic cutaneous leishmaniasis, IFN-gamma was infrequently observed in response to stimulation by all three fractions of amastigote SLA, but secretion of IL-4 was observed. These data indicate that first fraction of amastigote SLA is a strong inducer of primed human immune response to L. major, and may have a protective function.